Chengdu Kanghong Pharmaceuticals Group Co Ltd Tangible Net Worth Ratio

Latest as of June 2026: 94.8%

Chengdu Kanghong Pharmaceuticals Group Co Ltd tangible net worth ratio. Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has a Tangible Net Worth Ratio of 94.8% as of June 2026. This metric is calculated by deducting intangible assets (CN¥473.63 Million) from net assets (CN¥9.18 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check 002773 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Tangible NW Ratio

94.8%
Tangible equity / total equity

Net Assets (Equity)

CN¥9.18 Billion
CNY

Intangible Assets

CN¥473.63 Million
Goodwill, patents, brand value

Total Assets

CN¥9.94 Billion
CNY

Tangible Net Worth Ratio of Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)

Tangible net worth ratio of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025. This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's Tangible Net Worth Ratio has changed across 17 annual periods from 2009 to 2025. As of June 2026, the ratio stands at 94.8%, reflecting net assets of CN¥9.18 Billion with intangible assets of CN¥473.63 Million CNY. See Chengdu Kanghong Pharmaceuticals Group C working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Chengdu Kanghong Pharmaceuticals Group Co Ltd Tangible Net Worth Ratio by Year (2009–2025)

Chengdu Kanghong Pharmaceuticals Group Co Ltd tangible net worth ratio by year from 2009 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025, covering 17 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Chengdu Kanghong Pharmaceuticals Group C market capitalisation.

Year Tangible NW Ratio Net Assets (CNY) Intangible Assets Total Assets Change (pp)
2025 95.5% CN¥9.27 Billion CN¥413.59 Million CN¥9.92 Billion ▲ +0.2 pp
2024 95.3% CN¥8.65 Billion CN¥403.70 Million CN¥9.34 Billion ▲ +0.6 pp
2023 94.8% CN¥7.81 Billion CN¥408.95 Million CN¥8.53 Billion ▲ +0.5 pp
2022 94.3% CN¥6.91 Billion CN¥393.12 Million CN¥7.72 Billion ▲ +0.1 pp
2021 94.2% CN¥6.10 Billion CN¥351.83 Million CN¥6.96 Billion ▲ +0.3 pp
2020 94.0% CN¥5.76 Billion CN¥347.41 Million CN¥7.00 Billion ▲ +17.6 pp
2019 76.3% CN¥4.62 Billion CN¥1.09 Billion CN¥5.83 Billion ▼ -9.1 pp
2018 85.5% CN¥4.08 Billion CN¥592.65 Million CN¥5.19 Billion ▼ -3.8 pp
2017 89.3% CN¥3.54 Billion CN¥377.97 Million CN¥4.59 Billion ▼ -3.0 pp
2016 92.4% CN¥2.90 Billion CN¥221.46 Million CN¥3.76 Billion ▲ +0.4 pp
2015 92.0% CN¥2.52 Billion CN¥202.05 Million CN¥2.90 Billion ▲ +3.1 pp
2014 88.9% CN¥1.61 Billion CN¥178.35 Million CN¥1.94 Billion ▲ +1.9 pp
2013 87.0% CN¥1.39 Billion CN¥180.37 Million CN¥1.69 Billion ▲ +1.9 pp
2012 85.2% CN¥1.11 Billion CN¥164.25 Million CN¥1.48 Billion ▼ -1.2 pp
2011 86.4% CN¥936.39 Million CN¥127.72 Million CN¥1.30 Billion ▲ +3.2 pp
2010 83.1% CN¥624.85 Million CN¥105.38 Million CN¥991.06 Million ▲ +3.6 pp
2009 79.6% CN¥539.75 Million CN¥110.23 Million CN¥823.48 Million —
pp = percentage points